Korea Exchange · Healthcare
Korea United Pharm stock from India: price, numbers and tax
Korea United Pharm (033270) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
Korea United Pharm at a glance
- Price
- ₩17,860.00-₩110.00 (0.61%)
- Market cap
- ₩257.93B
- Day range
- ₩17,720.00 – ₩18,020.00
- P/E
- 3.63
- Dividend yield
- 3.42%
- Volume
- 11.17K
- 1 month
- -3.30%
- 6 months
- -10.39%
- YTD
- -6.35%
- 1 year
- -6.35%
- 5 years
- -62.68%
Korea United Pharm statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | ₩288.8B | ₩288.7B | ₩278.9B | ₩262.5B | ₩221.0B |
| Gross profit | ₩175.4B | ₩164.0B | ₩159.0B | ₩145.3B | ₩122.7B |
| Operating income | ₩48.9B | ₩56.3B | ₩54.9B | ₩48.2B | ₩33.2B |
| Net income | ₩38.3B | ₩32.5B | ₩48.3B | ₩45.3B | ₩28.6B |
| Earnings per share | ₩2,614.37 | ₩2,206.00 | ₩3,297.93 | ₩3,057.78 | ₩1,930.09 |
| EBITDA | ₩60.5B | ₩57.8B | ₩70.8B | ₩62.0B | ₩46.9B |
| Total assets | ₩519.5B | ₩473.9B | ₩468.9B | ₩417.9B | ₩380.0B |
| Total debt | ₩14.0B | ₩15.6B | ₩40.3B | ₩30.3B | ₩33.0B |
| Cash and short-term investments | ₩157.1B | ₩132.3B | ₩151.1B | ₩142.6B | ₩123.2B |
| Shareholders' equity | ₩454.6B | ₩406.2B | ₩378.7B | ₩337.9B | ₩300.7B |
| Operating cash flow | ₩51.1B | ₩26.8B | ₩50.6B | ₩63.8B | ₩44.1B |
| Free cash flow | ₩27.7B | ₩5.6B | ₩19.3B | ₩39.6B | ₩31.3B |
| Capital expenditure | −₩23.4B | −₩21.2B | −₩31.3B | −₩24.2B | −₩12.8B |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in KRW; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Kwang Dong Pharmaceutical | 009290.KS | ₩6,920.00 | ₩343.65B |
| Suheung | 008490.KS | ₩20,250.00 | ₩225.51B |
| Huons | 243070.KQ | ₩19,000.00 | ₩221.38B |
| Boditech Med | 206640.KQ | ₩9,790.00 | ₩212.52B |
| Daewon Pharmaceutical | 003220.KS | ₩8,190.00 | ₩175.54B |
| Hana Pharm | 293480.KS | ₩8,470.00 | ₩150.11B |
| Dongwha Pharm | 000020.KS | ₩5,360.00 | ₩148.57B |
| Jeil Pharmaceutical | 271980.KS | ₩10,050.00 | ₩147.78B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in Korea United Pharm from India
What Korea United Pharm does
Korea United Pharm Inc. is a South Korean enterprise dedicated to the development, production, and distribution of a wide array of pharmaceutical products. The company's extensive portfolio encompasses therapeutic solutions for various medical fields, such as the respiratory, musculoskeletal, gastrointestinal, cardiovascular, and central nervous systems, in addition to treatments for cancer, infections, allergies, and immune disorders. Korea United Pharm operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell Korea United Pharm shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the KRW/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.